Trends in health workers' compliance with outpatient malaria case-management guidelines across malaria epidemiological zones in Kenya, 2010-2016.


Journal

Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802

Informations de publication

Date de publication:
11 Nov 2020
Historique:
received: 12 05 2020
accepted: 02 11 2020
entrez: 12 11 2020
pubmed: 13 11 2020
medline: 22 6 2021
Statut: epublish

Résumé

Health workers' compliance with outpatient malaria case-management guidelines has been improving, specifically regarding the universal testing of suspected cases and the use of artemisinin-based combination therapy (ACT) only for positive results (i.e., 'test and treat'). Whether the improvements in compliance with 'test and treat' guidelines are consistent across different malaria endemicity areas has not been examined. Data from 11 national, cross-sectional, outpatient malaria case-management surveys undertaken in Kenya from 2010 to 2016 were analysed. Four primary indicators (i.e., 'test and treat') and eight secondary indicators of artemether-lumefantrine (AL) dosing, dispensing, and counselling were measured. Mixed logistic regression models were used to analyse the annual trends in compliance with the indicators across the different malaria endemicity areas (i.e., from highest to lowest risk being lake endemic, coast endemic, highland epidemic, semi-arid seasonal transmission, and low risk). Compliance with all four 'test and treat' indicators significantly increased in the area with the highest malaria risk (i.e., lake endemic) as follows: testing of febrile patients (OR = 1.71 annually; 95% CI = 1.51-1.93), AL treatment for test-positive patients (OR = 1.56; 95% CI = 1.26-1.92), no anti-malarial for test-negative patients (OR = 2.04; 95% CI = 1.65-2.54), and composite 'test and treat' compliance (OR = 1.80; 95% CI = 1.61-2.01). In the low risk areas, only compliance with test-negative results significantly increased (OR = 2.27; 95% CI = 1.61-3.19) while testing of febrile patients showed declining trends (OR = 0.89; 95% CI = 0.79-1.01). Administration of the first AL dose at the facility significantly increased in the areas of lake endemic (OR = 2.33; 95% CI = 1.76-3.10), coast endemic (OR = 5.02; 95% CI = 2.77-9.09) and semi-arid seasonal transmission (OR = 1.44; 95% CI = 1.02-2.04). In areas of the lowest risk of transmission and highland epidemic zone, none of the AL dosing, dispensing, and counselling tasks significantly changed over time. There is variability in health workers' compliance with outpatient malaria case-management guidelines across different malaria-risk areas in Kenya. Major improvements in areas of the highest risk have not been seen in low-risk areas. Interventions to improve practices should be targeted geographically.

Sections du résumé

BACKGROUND BACKGROUND
Health workers' compliance with outpatient malaria case-management guidelines has been improving, specifically regarding the universal testing of suspected cases and the use of artemisinin-based combination therapy (ACT) only for positive results (i.e., 'test and treat'). Whether the improvements in compliance with 'test and treat' guidelines are consistent across different malaria endemicity areas has not been examined.
METHODS METHODS
Data from 11 national, cross-sectional, outpatient malaria case-management surveys undertaken in Kenya from 2010 to 2016 were analysed. Four primary indicators (i.e., 'test and treat') and eight secondary indicators of artemether-lumefantrine (AL) dosing, dispensing, and counselling were measured. Mixed logistic regression models were used to analyse the annual trends in compliance with the indicators across the different malaria endemicity areas (i.e., from highest to lowest risk being lake endemic, coast endemic, highland epidemic, semi-arid seasonal transmission, and low risk).
RESULTS RESULTS
Compliance with all four 'test and treat' indicators significantly increased in the area with the highest malaria risk (i.e., lake endemic) as follows: testing of febrile patients (OR = 1.71 annually; 95% CI = 1.51-1.93), AL treatment for test-positive patients (OR = 1.56; 95% CI = 1.26-1.92), no anti-malarial for test-negative patients (OR = 2.04; 95% CI = 1.65-2.54), and composite 'test and treat' compliance (OR = 1.80; 95% CI = 1.61-2.01). In the low risk areas, only compliance with test-negative results significantly increased (OR = 2.27; 95% CI = 1.61-3.19) while testing of febrile patients showed declining trends (OR = 0.89; 95% CI = 0.79-1.01). Administration of the first AL dose at the facility significantly increased in the areas of lake endemic (OR = 2.33; 95% CI = 1.76-3.10), coast endemic (OR = 5.02; 95% CI = 2.77-9.09) and semi-arid seasonal transmission (OR = 1.44; 95% CI = 1.02-2.04). In areas of the lowest risk of transmission and highland epidemic zone, none of the AL dosing, dispensing, and counselling tasks significantly changed over time.
CONCLUSIONS CONCLUSIONS
There is variability in health workers' compliance with outpatient malaria case-management guidelines across different malaria-risk areas in Kenya. Major improvements in areas of the highest risk have not been seen in low-risk areas. Interventions to improve practices should be targeted geographically.

Identifiants

pubmed: 33176783
doi: 10.1186/s12936-020-03479-z
pii: 10.1186/s12936-020-03479-z
pmc: PMC7659071
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

406

Subventions

Organisme : Wellcome Trust
ID : 103602
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 212176
Pays : United Kingdom
Organisme : DELTAS Africa Initiative
ID : DEL-15-003

Références

Malar J. 2008 Sep 19;7:181
pubmed: 18803833
PLoS One. 2014 Apr 18;9(4):e95483
pubmed: 24748201
Malar J. 2011 Apr 02;10:76
pubmed: 21457570
PLoS One. 2011;6(9):e24781
pubmed: 21935464
Malar J. 2016 Feb 24;15:112
pubmed: 26911252
Malar J. 2017 Mar 1;16(1):95
pubmed: 28249580
Trop Med Int Health. 2008 Jun;13(6):784-7
pubmed: 18482078
Malar J. 2015 Dec 01;14:483
pubmed: 26628068
Malar J. 2016 Aug 04;15(1):396
pubmed: 27488343
BMC Public Health. 2015 Apr 10;15:352
pubmed: 25885211
Trop Med Int Health. 2009 Jul;14(7):766-74
pubmed: 19549001
Trop Med Int Health. 2013 Oct;18(10):1269-82
pubmed: 23937722
Am J Trop Med Hyg. 2004 Dec;71(6):715-22
pubmed: 15642960
Trop Med Int Health. 2002 Jan;7(1):45-52
pubmed: 11851954
Malar J. 2016 Jan 04;15:4
pubmed: 26728037
Trop Med Int Health. 2008 Jan;13(1):99-107
pubmed: 18291008
Malar J. 2017 Jan 23;16(1):40
pubmed: 28114942
PLoS One. 2014 Mar 24;9(3):e92782
pubmed: 24663961
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):128-32
pubmed: 18165484
Malar J. 2017 Jan 25;16(1):46
pubmed: 28122622
PLoS One. 2014 Feb 20;9(2):e89050
pubmed: 24586497
BMJ. 2009 Apr 20;338:b946
pubmed: 19380414
Ghana Med J. 2014 Jun;48(2):112-22
pubmed: 25667560
Am J Trop Med Hyg. 2018 Sep;99(3):670-679
pubmed: 29943717
Malar J. 2018 Sep 26;17(1):340
pubmed: 30257697
PLoS One. 2016 Jul 08;11(7):e0158780
pubmed: 27391594
Malar J. 2017 May 3;16(1):186
pubmed: 28468663
Malar J. 2015 Mar 01;14:97
pubmed: 25890202
Malar J. 2018 Dec 19;17(1):481
pubmed: 30567603
Trop Med Int Health. 2001 Jul;6(7):505-10
pubmed: 11469942
Malar J. 2013 Dec 10;12:446
pubmed: 24325267
Parasit Vectors. 2011 May 26;4:92
pubmed: 21615906
Pan Afr Med J. 2014 Dec 10;19:367
pubmed: 25932080
Malar J. 2016 Mar 15;15:163
pubmed: 26979286
BMC Public Health. 2012 Jan 06;12:11
pubmed: 22221821
PLoS One. 2015 May 22;10(5):e0127818
pubmed: 26000856
Trans R Soc Trop Med Hyg. 2013 Mar;107(3):176-82
pubmed: 23382275
Nature. 2017 Oct 26;550(7677):515-518
pubmed: 29019978
PLoS One. 2011 Jan 19;6(1):e16316
pubmed: 21283815
BMC Infect Dis. 2009 Nov 20;9:180
pubmed: 19930552
Malar J. 2011 May 20;10:136
pubmed: 21599880
PLoS One. 2015 Feb 17;10(2):e0107042
pubmed: 25689585
Malar J. 2013 Aug 26;12:293
pubmed: 23977904
Am J Epidemiol. 1998 Apr 1;147(7):694-703
pubmed: 9554609
J Infect Dis. 2005 Jun 1;191(11):1932-9
pubmed: 15871128
Clin Infect Dis. 2011 Oct;53(8):772-9
pubmed: 21921220
BMJ. 2008 Jan 26;336(7637):202-5
pubmed: 18199700
Malar J. 2013 Oct 25;12:371
pubmed: 24160186
PLoS One. 2015 Apr 10;10(4):e0123283
pubmed: 25860016
Malar J. 2009 Dec 02;8:275
pubmed: 19954537
Malar J. 2019 May 6;18(1):162
pubmed: 31060605
BMC Med. 2020 Jan 30;18(1):17
pubmed: 31996199
Malar J. 2014 Jul 09;13:261
pubmed: 25008574
BMC Public Health. 2017 May 18;17(1):470
pubmed: 28521798
Malar J. 2007 May 29;6:72
pubmed: 17535417
J Prim Health Care. 2012 Jun 01;4(2):166-73
pubmed: 22675704
Malar J. 2015 Jan 28;14:34
pubmed: 25627166

Auteurs

Beatrice Amboko (B)

KEMRI-Wellcome Trust Research Programme, P.O. Box 43640-00100, Nairobi, Kenya. BAmboko@kemri-wellcome.org.

Kasia Stepniewska (K)

WorldWide Antimalarial Resistance Network, Oxford, UK.
Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.

Peter M Macharia (PM)

KEMRI-Wellcome Trust Research Programme, P.O. Box 43640-00100, Nairobi, Kenya.

Beatrice Machini (B)

Division of National Malaria Programme, Ministry of Health, Nairobi, Kenya.

Philip Bejon (P)

KEMRI-Wellcome Trust Research Programme, P.O. Box 43640-00100, Nairobi, Kenya.
Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.

Robert W Snow (RW)

KEMRI-Wellcome Trust Research Programme, P.O. Box 43640-00100, Nairobi, Kenya.
Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.

Dejan Zurovac (D)

KEMRI-Wellcome Trust Research Programme, P.O. Box 43640-00100, Nairobi, Kenya.
Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH